Avantra Biosciences, a leading innovator in protein diagnostics, announced their first shipments of the new Q400 Biomarker Workstation and the innovative Angio Qx BioChip Immunoassay. The system provides quantitative protein biomarker results for ten analytes in less than an hour, requiring less than five minutes for sample preparation. Multiplex protein assays can be helpful in evaluating the association between elevated protein levels, patient phenotype and drug response.

The Angio Qx Immunoassay is a member of the Avantra QPDx biomarker detection product line for use with the Q400 Biomarker Workstation. This platform consists of a completely self-contained immunoassay BioChip and instrument, for use in the automated measurement of key biomarkers.

Avantra is currently working with leading experts and institutions on the development of additional biomarker panels directed at specific diseases with an emphasis in the field of oncology for Research Use Only (RUO). Avantra intends to seek regulatory approval for its assay technologies in the future.

The power and simplicity of Avantra’s QPDx platform offers users a rapid, easy-to-use, high quality bench top quantitative multiplex protein assay platform with extremely low CVs and very little setup time.

“The initial shipment of Avantra’s QPDx biomarker product line represents the first milestone in Avantra’s strategy to develop a suite of oncology focused multiplex biomarker panels. We see a tremendous opportunity for our QPDx product line and we are excited about the work we are doing with our partners to commercialize additional oncology specific biomarker panels” says Brian McKernan, CEO of Avantra

Avantra Biosciences is a privately held diagnostics company that has pioneered next generation technology for protein biomarker analysis. Initially focused on oncology, Avantra's integrated system enables scientists and clinicians to perform multiplex biomarker analysis for Research Use Only (RUO) from their lab bench or clinical trial site.